ADAP241220P1000
- 0.30
- -0.05-14.29%
Adaptimmune Therapeutics Newsroom
Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics Analyst Ratings
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim
Wells Fargo Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
TD Cowen Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating
Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Cuts Target Price to $3.5
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4
Adaptimmune Therapeutics Analyst Ratings
Leerink Partners Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
A Quick Look at Today's Ratings for Adaptimmune Therapeutics(ADAP.US), With a Forecast Between $1 to $4
Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)
Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline